Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research [0.03%]
当前白血病小鼠体内模型和先进体外模型的评估
Xenia Bubnova,Lauren Hope,Helen Wheadon
Xenia Bubnova
Leukaemia is caused by genetic mutations within haematopoietic stem and progenitor cells, leading to the production of immature blasts. While mouse models have been instrumental in studying disease mechanisms and testing therapies, their li...
Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions [0.03%]
低丙种球蛋白血症在淋巴系统恶性肿瘤中的深度探索：病理生理、临床意义、管理选择和未来方向
Alex Wonnaparhown,Talal Hilal,Albert Chong et al.
Alex Wonnaparhown et al.
The treatment of lymphoid malignancies is rapidly advancing with recognition of hypogammaglobulinemia (HG) and increased infection risk with the use of cellular-targeted therapies, such as chimeric antigen receptor (CAR) T cell and bispecif...
Baher Krayem,Avraham Frisch,Netanel Horowitz
Baher Krayem
The prognosis of patients with AML varies significantly with age, driven by biological heterogeneity and age-associated factors such as comorbidities, functional status, and hospitalization burden. Many novel therapies have been approved in...
Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights [0.03%]
低危MDS的动态景观导航：进展与新兴见解
Alain Mina,Yazan Madanat,Yasmin Abaza et al.
Alain Mina et al.
Myelodysplastic syndromes/neoplasms (MDS) are a group of clonal myeloid malignancies characterized by ineffective hematopoiesis, cytopenias, and an increased risk of transformation to acute myeloid leukemia (AML). In lower-risk (LR) MDS, as...
Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies [0.03%]
从病理生理学到前沿疗法：对抗多发性骨髓瘤骨病
Sophie Roux,Françoise Debiais,Marie-Hélène Vieillard
Sophie Roux
Bone involvement in multiple myeloma (MM) is marked by osteolysis, driven by excessive bone resorption and a profound suppression of bone formation. Interactions between MM cells and the bone microenvironment-mediated by integrins,chemokine...
Yesim Dargaud,Sebastien Lobet,Nathalie Roussel et al.
Yesim Dargaud et al.
Hemophilia A and B are rare X-linked bleeding disorders caused by coagulation factor deficiencies, leading to joint bleeding, synovial hypertrophy and chronic hemophilic arthropathy marked by progressive cartilage and bone damage. Musculosk...
Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research [0.03%]
患者报告结果指标：推进轻链型(AL)淀粉样变临床研究的缺失环节
Tobias Dittrich,Lina Weinert,Anita D&#x;Souza
Tobias Dittrich
Systemic light chain (AL) amyloidosis often results in multi-organ dysfunction and significant morbidity. Clinical assessments may not capture the full impact of disease and treatment on patients. Patient-reported outcomes (PROs) can help f...
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies [0.03%]
血小板在静脉血栓形成中的关键作用：发病机制、临床现状和新兴治疗策略
Shuang Liu,Yan Shen,Jiayi Chen et al.
Shuang Liu et al.
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a complex vascular disorder with high morbidity and mortality, driven by Virchow's Triad: blood stasis, hypercoagulability, and endothelia...
Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody [0.03%]
从抑制到消除：AL型淀粉样变性症的新兴治疗方法——关于CAEL-101抗体的人体早期数据和药代动力学的全面综述
Anam Ashfaque,Yara Shatnawi,Shahzad Raza et al.
Anam Ashfaque et al.
Light chain (AL amyloidosis) is a rare disorder characterized by the deposition of misfolded light chains in various organs, causing progressive organ damage. Current therapeutic agents do not remove amyloid aggregates already present in th...
The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments [0.03%]
成人原发性免疫性血小板减少症管理新时代：当前和新兴治疗方法的叙事综述
Tomás José González-López,Drew Provan
Tomás José González-López
The purpose of this review is to highlight the treatments currently available and those under- going evaluation in clinical trials for the treatment of ITP in order to achieve optimal use of the various existing ITP treatments. Specifically...